The current standard-of-care [18F]FDG PET/CT, which targets glucose metabolism in tumors, and the recently approved [18F]FES PET/CT, as a biomarker of estrogen receptor expression, have been at the forefront of breast cancer management. This evidence concerns the gene ESR1 and breast carcinoma.